Masked Diabetes Insipidus Hidden by Severe Hyponatremia: A Case of Pituitary Metastasis of Lung Adenocarcinoma.
Journal
The American journal of case reports
ISSN: 1941-5923
Titre abrégé: Am J Case Rep
Pays: United States
ID NLM: 101489566
Informations de publication
Date de publication:
18 Dec 2020
18 Dec 2020
Historique:
entrez:
18
12
2020
pubmed:
19
12
2020
medline:
15
5
2021
Statut:
epublish
Résumé
BACKGROUND Hyponatremia is an electrolyte disorder frequently encountered by clinicians. Secondary adrenal insufficiency due to pituitary metastatic tumors should be considered as an alternative diagnosis when clinicians encounter patients with lung cancer who demonstrate hyponatremia. However, masked central diabetes insipidus should also be considered to prevent critical dehydration when glucocorticoid replacement therapy will be initiated. CASE REPORT A 70-year-old man with advanced lung adenocarcinoma demonstrated high-grade hyponatremia of 122 mmol/L. Magnetic resonance imaging disclosed a metastatic pituitary tumor and endocrinological examinations confirmed panhypopituitarism, including secondary adrenal insufficiency. Hydrocortisone replacement revealed masked diabetes insipidus with elevation of serum sodium levels that reached 151 mmol/L. Desmopressin administration was required to prevent water depletion and to immediately ameliorate the hypernatremia. CONCLUSIONS This is the first case report of masked diabetes insipidus that demonstrated high-grade hyponatremia. Secondary adrenal insufficiency can mask the hypernatremia that is a typical manifestation of diabetes insipidus. Physicians should consider adrenal insufficiency and diabetes insipidus due to pituitary metastasis of advanced malignancies, even when they encounter patients with hyponatremia.
Identifiants
pubmed: 33335085
pii: 928113
doi: 10.12659/AJCR.928113
pmc: PMC7755591
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e928113Références
Endocr Connect. 2018 Aug 23;:
pubmed: 30139817
Oxf Med Case Reports. 2016 Jun 01;2016(6):125-9
pubmed: 27274855
Am J Case Rep. 2019 Feb 17;20:207-211
pubmed: 30772889
Ther Adv Med Oncol. 2017 Nov;9(11):711-719
pubmed: 29344107
J Clin Endocrinol Metab. 2004 Feb;89(2):574-80
pubmed: 14764764
BMJ Case Rep. 2015 Jan 22;2015:
pubmed: 25612752
Eur J Cancer. 2020 May;130:198-203
pubmed: 32229416
Lancet. 2017 Jan 21;389(10066):299-311
pubmed: 27574741
Heliyon. 2019 May 29;5(5):e01783
pubmed: 31193734
J Clin Endocrinol Metab. 2014 Nov;99(11):4027-36
pubmed: 25140404
Best Pract Res Clin Endocrinol Metab. 2016 Mar;30(2):189-203
pubmed: 27156758
J Am Soc Nephrol. 2017 May;28(5):1340-1349
pubmed: 28174217
Pituitary. 2014 Dec;17(6):575-87
pubmed: 24337713
Pituitary. 2018 Oct;21(5):463-473
pubmed: 29974330
Ann Endocrinol (Paris). 2017 Dec;78(6):490-494
pubmed: 29174931
BMC Endocr Disord. 2019 Oct 29;19(1):114
pubmed: 31664980
World J Oncol. 2015 Jun;6(3):375-377
pubmed: 28983332
Clin Chim Acta. 2020 Jun;505:78-91
pubmed: 32035851
Jpn J Clin Oncol. 2017 May 1;47(5):463-466
pubmed: 28334791